<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> SJMN91-06159023 </DOCNO><ACCESS> 06159023 </ACCESS><LEADPARA>  Genentech Inc. of South San Francisco said Thursday its heart attack drug TPAhas been approved for marketing in Japan. Two large Japanese pharmaceuticalcompanies, Mitsubishi Kasei Corp. and Kyowa Hakko Co. Ltd., will handle finalmanufacturing, packaging and marketing. The genetically engineered drug, whichdissolves blood clots that cause heart attacks, has been approved for sale at$2,250 a dose, about equivalent to its U.S. price. Heart attacks strike about140,000 Japanese each year.  </LEADPARA><SECTION>  Business  </SECTION><HEADLINE>  GENENTECH GETS OK TO SELL TPA IN JAPAN  </HEADLINE><MEMO>  Financial Digest  </MEMO><BYLINE>  Mercury News Staff and Wire Reports  </BYLINE><COUNTRY>  USA  </COUNTRY><EDITION>  Morning Final  </EDITION><CODE>  SJ  </CODE><NAME>  San Jose Mercury News  </NAME><PUBDATE>   910607  </PUBDATE> <DAY>  Friday  </DAY><MONTH>  June  </MONTH><PG.COL>  13D  </PG.COL><PUBYEAR>  1991  </PUBYEAR><REGION>  WEST  </REGION><STATE>  CA  </STATE><WORD.CT>  77  </WORD.CT><DATELINE>  Friday June 7, 199100159023,SJ1  </DATELINE><COPYRGHT>  Copyright 1991, San Jose Mercury News  </COPYRGHT><LIMLEN>  1  </LIMLEN><LANGUAGE>  ENG  </LANGUAGE></DOC>